½ÃÀ庸°í¼­
»óǰÄÚµå
1668036

¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø : Á¦Ç°º°, ¿ëµµº°, Áö¿ªº°, °æÀﺰ(2020-2035³â)

Azithromycin Dihydrate Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2020-2035F

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: TechSci Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 183 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ¼¼°è ½ÃÀåÀº 2024³â 4,440ÅæÀ¸·Î Æò°¡µÇ°í 2035³â¿¡´Â 8,280Åæ¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 5.89%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2035³â
½ÃÀå ±Ô¸ð : 2024³â 4,440Åæ
½ÃÀå ±Ô¸ð : 2035³â 8,280Åæ
CAGR : 2025-2035³â 5.89%
±Þ¼ºÀå ºÎ¹® ÀǾàǰ µî±Þ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°
ÃÖ´ë ½ÃÀå ºÏ¹Ì

¾ÆÁöÆ®·Î¸¶À̽ÅÀÇ À¯µµÃ¼ÀÎ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°Àº ±¤¹üÀ§ÇÑ Ç×±Õ È°¼ºÀ¸·Î ÀÎÇØ Á¦¾à »ê¾÷¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. È£Èí±â °¨¿°, ÇǺΠ°¨¿°, ¼ºº´ µîÀÇ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ¿øµ¿·ÂÀº ¼¼°è ÇコÄɾ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼¼±Õ¼º °¨¿°ÀÇ À¯º´·ü Áõ°¡, ƯÈ÷ ½ÅÈï °æÁ¦±Ç¿¡¼­ Àú·ÅÇÑ Ä¡·á ¿É¼ÇÀÇ Çʿ伺 µîÀ̸ç, 2022³â EU »ê¾÷ R&D ÅõÀÚ ½ºÄھµå¿¡ µû¸£¸é ÀÇ·á »ê¾÷Àº 2021³â¿¡ ¾à 2,353¾ï À¯·Î¸¦ ¿¬±¸°³¹ß(R&D)¿¡ ÇÒ´çÇß½À´Ï´Ù. ÀÌ´Â Àü ¼¼°è ±â¾÷ R&D ÁöÃâÀÇ 21.5%¿¡ ÇØ´çÇÕ´Ï´Ù.

Áö¿ªÀûÀ¸·Î ºÏ¹Ì¿Í À¯·´Àº ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó¿Í ¾à¹° ³»¼º °¨¿°ÀÇ È®»êÀ¸·Î ÀÎÇØ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°ÀÇ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á ¼­ºñ½º Á¢±Ù¼º °³¼±, Àα¸ Áõ°¡, ¼¼±Õ °¨¿°·ü Áõ°¡·Î ÀÎÇØ °¡Àå ºü¸¥ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ¿Â¶óÀÎ ¾à±¹ ¹× E-Commerce Ç÷§ÆûÀÇ È®´ë·Î ÀÎÇØ ÀÇ·á ÀÎÇÁ¶ó°¡ Á¦ÇÑµÈ Áö¿ª¿¡¼­ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°ÀÇ Á¢±Ù¼ºÀÌ °³¼±µÇ°í ÀÖ½À´Ï´Ù.

½ÃÀåÀº ¶ÇÇÑ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°ÀÇ Á¦Çü ¹× Àü´Þ¿¡ ´ëÇÑ ±â¼ú Çõ½ÅÀ» ¸ñ°ÝÇϰí ÀÖÀ¸¸ç, ¿©±â¿¡´Â ¾à¹°ÀÇ È¿´É°ú ȯÀÚ ¼øÀÀµµ¸¦ Çâ»ó½ÃŰ´Â »õ·Î¿î Á¦Çü ¹× º´¿ë¿ä¹ýÀÇ °³¹ßÀÌ Æ÷ÇԵ˴ϴÙ. ¶ÇÇÑ, ƯÇã ¸¸·á·Î ÀÎÇÑ Á¦³×¸¯ ÀǾàǰÀÇ Áõ°¡·Î ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°ÀÇ °¡°ÝÀÌ Àú·ÅÇØÁ® ´õ ¸¹Àº ȯÀÚµéÀÌ ½±°Ô Á¢±ÙÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±×·¯³ª ±ÔÁ¦ÀÇ º¹À⼺, Ç×±ÕÁ¦ ³»¼ºÀÇ ÃâÇö, ƯÁ¤ Áö¿ª¿¡¼­ ´õ ³ªÀº ´ëüǰÀÇ Çʿ伺°ú °°Àº µµÀü°úÁ¦´Â ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ¼¼°è ½ÃÀåÀº Áö¼ÓÀûÀÎ ÀÇ·á ¼ö¿ä¿Í ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÁÖ¿ä ½ÃÀå ÃËÁø¿äÀÎ

¼¼±Õ °¨¿° Áõ°¡

ÁÖ¿ä ½ÃÀå °úÁ¦

±ÔÁ¦ À庮°ú ½ÃÀå Á¢±Ù¼º

ÁÖ¿ä ½ÃÀå µ¿Çâ

¿Â¶óÀÎ ¾à±¹ ¹× E-Commerce Ç÷§ÆûÀÇ ¼ºÀå

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
    • ±Ý¾×º°
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
    • Á¦Ç°º°(API µî±Þ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°, ÀǾàǰ µî±Þ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°, ¿¬±¸ µî±Þ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹°)
    • ¿ëµµº°(Ç×»ýÁ¦, È£Èí±â °¨¿°Áõ, ¼º°¨¿°Áõ, ÇǺΠ°¨¿°Áõ)
    • ±â¾÷º°(2024³â)
    • Áö¿ªº°
  • ½ÃÀå ¸Ê

Á¦6Àå ºÏ¹ÌÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ºÏ¹Ì : ±¹°¡º° ºÐ¼®
    • ¸ß½ÃÄÚ
    • ij³ª´Ù

Á¦7Àå À¯·´ÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • À¯·´ : ±¹°¡º° ºÐ¼®
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º° ºÐ¼®
    • Àεµ
    • Çѱ¹
    • ÀϺ»
    • È£ÁÖ

Á¦9Àå ³²¹ÌÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • ³²¹Ì : ±¹°¡º° ºÐ¼®
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¾ÆÁöÆ®·Î¸¶À̽ŠÀ̼öÈ­¹° ½ÃÀå Àü¸Á

  • ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø
  • ½ÃÀå Á¡À¯À²°ú ¿¹Ãø
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º° ºÐ¼®
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®

Á¦11Àå ½ÃÀå ¿ªÇÐ

  • ¼ºÀå ÃËÁø¿äÀÎ
  • °úÁ¦

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

  • ÀμöÇÕº´(ÀÖ´Â °æ¿ì)
  • Á¦Ç° ¹ß¸Å(ÀÖ´Â °æ¿ì)
  • ÃÖ±Ù µ¿Çâ

Á¦13Àå Porter's Five Forces ºÐ¼®

  • ¾÷°è³» °æÀï
  • ½Å±Ô Âü¿©ÀÇ °¡´É¼º
  • °ø±Þ¾÷üÀÇ ´É·Â
  • °í°´ÀÇ ´É·Â
  • ´ëüǰÀÇ À§Çù

Á¦14Àå °æÀï ±¸µµ

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Arbindo Pharma Limited
  • Mylan N.V.

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå Á¶»ç ȸ»ç ¼Ò°³ ¹× ¸éÃ¥»çÇ×

ksm 25.03.19

The Global Azithromycin Dihydrate Market was valued at 4.44 thousand tonnes in 2024 and is projected to reach 8.28 thousand tonnes by 2035, growing at a compound annual growth rate (CAGR) of 5.89% during the forecast period.

Market Overview
Forecast Period2026-2035
Market Size 20244.44 Thousand Tonnes
Market Size 20358.28 Thousand Tonnes
CAGR 2025-20355.89%
Fastest Growing SegmentPharmaceutical Grade Azithromycin Dihydrate
Largest MarketNorth America

Azithromycin dihydrate, a derivative of azithromycin, plays a critical role in the pharmaceutical industry due to its broad-spectrum antimicrobial activity. It is widely used in the treatment of respiratory, skin, and sexually transmitted infections, among others. This market is primarily driven by increasing global healthcare awareness, the rising incidence of bacterial infections, and the need for affordable treatment options, especially in emerging economies. According to the 2022 EU Industrial R&D Investment Scoreboard, the health industry allocated approximately €235.3 billion to research and development (R&D) in 2021, which represented 21.5% of global business R&D expenditure.

Geographically, North America and Europe are leading the demand for azithromycin dihydrate, owing to their advanced healthcare infrastructure and the growing prevalence of drug-resistant infections. However, the Asia-Pacific region is expected to experience the fastest growth, driven by improving healthcare access, a growing population, and increasing rates of bacterial infections. Moreover, the expansion of online pharmacies and e-commerce platforms has improved access to azithromycin dihydrate in regions with limited healthcare infrastructure.

The market is also witnessing innovations in the formulation and delivery of azithromycin dihydrate, including the development of new dosage forms and combination therapies that enhance the drug's efficacy and patient compliance. Additionally, the increasing availability of generics, due to patent expirations, is making azithromycin dihydrate more affordable and accessible to a wider patient population. However, challenges such as regulatory complexities, the emergence of antimicrobial resistance, and the need for better alternatives in certain regions may hinder market growth. Despite these challenges, the Global Azithromycin Dihydrate Market is expected to continue its expansion due to ongoing medical demand and advancements in drug development.

Key Market Drivers

Rising Incidence of Bacterial Infections

The increasing prevalence of bacterial infections is one of the major drivers of the Global Azithromycin Dihydrate Market. With global population growth and urbanization, the spread of infectious diseases is becoming more widespread. Respiratory infections, including pneumonia, bronchitis, and sinusitis, are common conditions treated with azithromycin, which is known for its broad-spectrum antibiotic properties. Azithromycin dihydrate's effectiveness against a wide range of bacterial pathogens makes it a critical treatment option. The growing number of bacterial infections, particularly in emerging economies with expanding healthcare systems, is increasing demand for antibiotics such as azithromycin dihydrate. Furthermore, environmental factors such as rising air pollution are contributing to higher rates of respiratory infections, further driving the market need for azithromycin. Antibiotic resistance remains a growing global concern, and azithromycin dihydrate's ability to treat multi-drug-resistant organisms reinforces its role in the global healthcare system. This rising burden of bacterial infections continues to support market growth.

Key Market Challenges

Regulatory Barriers and Market Access

A significant challenge facing the Global Azithromycin Dihydrate Market is the complex and varied regulatory requirements across different regions. Regulatory authorities such as the U.S. FDA, EMA, and other local agencies have stringent standards for approval, including Good Manufacturing Practices (GMP) compliance and safety guidelines. Prolonged approval timelines can delay market entry and slow the pace of innovation. Moreover, increasing regulatory focus on antibiotic resistance and usage has led to stricter guidelines for azithromycin dihydrate's application. For instance, the Central Drug Standard Control Organisation (CDSCO) in India has flagged several batches of azithromycin dihydrate for not meeting quality standards. These regulatory hurdles can impede market access, affecting both the speed of innovation and competition in the market.

Key Market Trends

Growth of Online Pharmacies and E-commerce Platforms

The rise of online pharmacies and e-commerce platforms has become a key driver of the Global Azithromycin Dihydrate Market. With the increasing popularity of digital health services, patients now have greater access to medications such as azithromycin dihydrate through online pharmacies. This has revolutionized the pharmaceutical sector, especially in regions where traditional pharmacies are scarce or hard to reach. The convenience of online shopping, alongside the ability to compare prices and read reviews, has made it easier for consumers to obtain azithromycin dihydrate from trusted online sources, expanding its reach. Additionally, e-commerce platforms offer home delivery services, a benefit especially appreciated during the COVID-19 pandemic when patients preferred to avoid in-person pharmacy visits. Online pharmacies also offer competitive pricing, which is particularly advantageous in developing regions where affordability is critical. The growth of telemedicine further contributes to this trend, as virtual consultations with healthcare providers often result in prescriptions for antibiotics like azithromycin dihydrate that patients can easily order online. As digital infrastructure improves, the accessibility of azithromycin dihydrate through online platforms will continue to increase, driving market growth.

Key Market Players

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Arvindo Pharma Limited
  • Mylan N.V.

Report Scope

In this report, the Global Azithromycin Dihydrate Market has been segmented as follows:

By Product:

  • API Grade Azithromycin Dihydrate
  • Pharmaceutical Grade Azithromycin Dihydrate
  • Research Grade Azithromycin Dihydrate

By Application:

  • Antibiotics
  • Respiratory Infections
  • Sexually Transmitted Diseases
  • Skin Infections

By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: In-depth analysis of major players in the Global Azithromycin Dihydrate Market.

Available Customizations

TechSci Research offers customization options for the Global Azithromycin Dihydrate Market report based on specific company needs. Customization options include:

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Azithromycin Dihydrate Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (API Grade Azithromycin Dihydrate, Pharmaceutical Grade Azithromycin Dihydrate, Research Grade Azithromycin Dihydrate)
    • 5.2.2. By Application (Antibiotics, Respiratory Infections, Sexually Transmitted Diseases, Skin Infections)
    • 5.2.3. By Company (2024)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Azithromycin Dihydrate Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Azithromycin Dihydrate Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Azithromycin Dihydrate Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Azithromycin Dihydrate Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Azithromycin Dihydrate Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Azithromycin Dihydrate Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Azithromycin Dihydrate Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Azithromycin Dihydrate Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Azithromycin Dihydrate Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Azithromycin Dihydrate Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia-Pacific Azithromycin Dihydrate Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Azithromycin Dihydrate Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Azithromycin Dihydrate Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Azithromycin Dihydrate Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Azithromycin Dihydrate Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Azithromycin Dihydrate Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Azithromycin Dihydrate Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Azithromycin Dihydrate Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Azithromycin Dihydrate Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Azithromycin Dihydrate Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Azithromycin Dihydrate Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Azithromycin Dihydrate Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Azithromycin Dihydrate Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Azithromycin Dihydrate Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Pfizer Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Teva Pharmaceutical Industries Ltd.
  • 14.3. Sandoz International GmbH
  • 14.4. Arbindo Pharma Limited
  • 14.5. Mylan N.V.

15. Strategic Recommendations

16. About Us & Disclaimer

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦